Nanoparticles development for pulmonary vaccination: Challenges and opportunities

سال انتشار: 1400
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 271

فایل این مقاله در 13 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_NAMJ-8-1_001

تاریخ نمایه سازی: 6 اردیبهشت 1400

چکیده مقاله:

Pulmonary vaccination is unique immune system protection treatment for the respiratory tract. Lungs contain large surface area for interaction with antigens. Nanoparticles as efficient drug carriers have been used for pulmonary vaccination. These structures contribute to the process either by encapsulating, dissolving, surface adsorbing or chemically attaching the active ingredients. Development of pulmonary vaccines via sub-micron particles has been investigated in this study. The nanoparticles deposited on the respiratory mucus, based on their size and charge, are either locally trapped or diffuse freely. Therefore, different mechanisms of particle deposition are defined based on the particle size and surface charges. Advantages and disadvantages of nanoparticles preparation methods as they pertain to pulmonary vaccine applications are comprehensively depicted. The adverse side effects of nanoparticles encountering immune cells is also discussed. Finally, the side effects and challenges of nano-pulmonary vaccines are discussed, offering a series practical suggestion for further industrial development and manufacturing of nanoparticle-empowered pulmonary vaccines.

نویسندگان

Narges Ghobadi

Department of Microbiology, Faculty of Basic Sciences, Hamedan Branch, Islamic Azad University, Hamedan, Iran

Sajjad Ghobadi

Department of Chemical and Life Science engineering, Virginia commonwealth University, USA

Michael B. Burkholder

Department of Chemical and Life Science engineering, Virginia commonwealth University, USA

Reza Habibipour

Department of Microbiology, Faculty of Basic Sciences, Hamedan Branch, Islamic Azad University, Hamedan, Iran

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • 1. Wouter FT, Kersten GF, Frijlink HW, Hinrichs WL, de ...
  • 2. Kunda NK, Somavarapu S, Gordon SB, Hutcheon GA, Saleem ...
  • 3. Shiehzadeh F, Tafaghodi M. Dry Powder form of Polymeric ...
  • 4. Catherine A, Rahhal TB, Robbins GR, Kai MP, Shen ...
  • 5. Fytianos K, Drasler B, Blank F, von Garnier C, ...
  • 6. Orga PL, Faden H, Welliver RC. Vaccination Strategies for ...
  • 7. Shakya AK, Chowdhury MYE, Tao W, Gill HS. Mucosal ...
  • 8. Thakur A, Foged C, Nanoparticles for mucosal vaccine delivery. ...
  • 9. Muralidharan P, Mallory E, Malapit M, Hayes DJ, Mansour ...
  • 10. Meenach SA, Anderson KW, Zach Hilt J, McGarry RC, ...
  • 11. Osman R, Kan PL, Awad G, Mortada N, El-Shamy ...
  • 12. El-Sherbiny IM, Charles Smyth HD. Controlled release pulmonary administration ...
  • 13. Chono S, Suzuki H, Togami K, Morimoto K. Efficient ...
  • 14. Insulin inhalation—Pfizer/Nektar therapeutics: Hmr 4006, inhaled peg-insulin—Nektar, PEGylated insulin—Nektar. ...
  • 15. Padmanabh HP, Development of adjuvanted influenza vaccines for pulmonary ...
  • 16. Audouy SAL, van der Schaaf G, Hinrichs WL, Frijlink ...
  • 17. Wee JLK., Scheerlinck JP, Snibson KJ, Edwards S, Pearse ...
  • 18. C.L. Hardy, J.S. Lemasurier, R. Mohamud, J. Yao, S.D. ...
  • 19. Li S.D, Huang L. Nanoparticles evading the reticuloendothelial system: ...
  • 20. Petros R.A., DeSimone J.M., Strategies in the design of ...
  • 21. Verhoef JJF, Groot AM, van Moorsel M, Ritsema J, ...
  • 22. S.P. Vyas, P.N. Gupta. Implication of nanoparticles/microparticles in mucosal ...
  • 23. Makadia H.K, Siegel S.J. Poly lactic-co-glycolic acid (PLGA) as ...
  • 24. Jiao Y, Pang X, Liu M, Zhang B, Li ...
  • 25. Bhide Y, Tomar J, Wei D, Vries-Idema J, W. ...
  • 26. Lu D, J Hickey A. Pulmonary vaccine delivery. Expert ...
  • 27. Hellfritzsch M, Scherlie R. Mucosal Vaccination via the Respiratory ...
  • 28. Tynea AS, Chan JG, Shanahan ER, Atmosukarto I, Chan ...
  • 29. Berlin JM, Tour JM. Development of novel drug delivery ...
  • 30. Wu M, Zhao H, Li M, Yue Y, Xiong ...
  • 31. Dhaka S, Renu S, Ghimire S, Shaan Lakshmanapp Y, ...
  • 32. Rose F, Wern J E, Gavins F, Andersen P, ...
  • 33. Cheung R.C, Ng T.B, Wong J.H, Chan W.Y. Chitosan: ...
  • 34. Riaz Rajoka MS, Zhao L, Mehwish HM, Wu Y, ...
  • 35. Tafaghodi M, Saluja V, Kersten G F, Kraan H, ...
  • 36. Marasini N, Ghaffar K A, Giddam A K, Batzloff ...
  • 37. Nevagi R J, Khalil Z J, Hussein W M, ...
  • 38. Okamoto S, Matsuura M, Akagi T, Akashi M, Tanimoto ...
  • 39. Chowdhury M Y E, Kim T H, Uddin M ...
  • 40. Mummert M E, Immunologic roles of hyaluronan. Immunol Res. ...
  • 41. Singh M., Briones M, O’Hagan D T. A novel ...
  • 42. Fan Y, Sahdev P, Ochy L J, Akerberg J, ...
  • 43. Nochi T, Yuki Y, Takahashi H, Sawada S, Mejima ...
  • 44. Fukuyama Y, Yuki Y, Katakai Y, Harada N, Takahashi ...
  • 45. Nagatomo D, Taniai M, Ariyasu H, Taniguchi M, Aga ...
  • 46. Blank F, Fytianos K, Seydoux E, Fink A, Von ...
  • 47. Hu K, Elvander M, Merza M, Åkerblom L, Brandenburg ...
  • 48. Tak W. Mak, Mary E. Saunders and Bradley D. ...
  • 49. Fujita Y, Taguchi H. Nanoparticle-Based Peptide Vaccines, Book Chap. ...
  • 50. Helgeby A, C Robson N, M. Donachie A, Beackock-Sharp ...
  • 51. Abdelkader H, Ismail S, Kamal A, G. Alany R, ...
  • 52. V. Li A, J. Moon J, Abraham W, Suh ...
  • 53. Irvine DJ, Hanson MC, Rakhra K, Tokatlian T. Synthetic ...
  • 54. Kunda N, M. Alfagih I, Rachel Dennison S, M. ...
  • 55. Muttil P, Prego C, Garcia-Contreras L, Pulliam B, Fallon ...
  • 56. Ross KA. Synthetic nanoparticle-based vaccines against respiratory pathogens, Lova ...
  • 57. Kunda N K, Alfagih IM, Miyaji EN, Figueiredo DB, ...
  • 58. Ozeki T, Tagami T, Drug/polymer nanoparticles prepared using unique ...
  • 59. Sarei F, Dounighi NM, Zolfagharian H, Khaki P, Bidhendi ...
  • 60. Bivas-Benita M, van Meijgaarden KE, Franken KL, Junginger HE, ...
  • 61. Blank F, Stumbles P, von Garnier C, Opportunities and ...
  • 62. Jorquera PA, Tripp RA. Synthetic Biodegradable Microparticle and Nanoparticle ...
  • 63. Lennart Buske SD. Chitosan as adjuvant and particle forming ...
  • 64. Silva A S, Tavares TM, Aguiar-Ricardo A. Sustainable strategies ...
  • 65.Wang J, Huang X, Li FR. Impaired dendritic cell functions ...
  • 66. Hammad H, Lambrecht BN. Lung dendritic cell migration. Adv ...
  • 67. Von Garnier C. Nanoparticles in the Respiratory Tract: Modulation ...
  • 68. Sou T. New developments in dry powder pulmonary vaccine ...
  • 69. Hugh DC, (Eds.). Pulmonary drug delivery, medicine for inhalation ...
  • 70. F Tonnis W, J Lexmond A, W Frijlink H, ...
  • 71. Lu D, J Hickey A. Pulmonary vaccine delivery. Expert ...
  • 72. Saleem I, Petkar K, Somavarapu S. Rationale for Pulmonary ...
  • 73. Roberts RA, Shen T, Allen IC, Hasan W, DeSimone ...
  • نمایش کامل مراجع